Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Abstract Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based chemotherapy. We wished to determine if...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. Migeotte, V. Dufour, A. van Maanen, M. Berliere, J. L. Canon, D. Taylor, F. P. Duhoux
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Metastatic breast cancer Line of treatment T-DM1 Progression-free survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/935991f59d184ddaad6383fdb13febcd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:935991f59d184ddaad6383fdb13febcd
record_format	dspace
spelling	oai:doaj.org-article:935991f59d184ddaad6383fdb13febcd2021-11-14T12:30:39ZImpact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer10.1186/s12885-021-08950-x1471-2407https://doaj.org/article/935991f59d184ddaad6383fdb13febcd2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08950-xhttps://doaj.org/toc/1471-2407Abstract Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based chemotherapy. We wished to determine if the line of treatment in which T-DM1 is administered has an impact on progression-free survival (PFS) and in particular, if prior treatment with capecitabine/lapatinib or pertuzumab modifies PFS of further treatment with T-DM1. Patients and methods We performed a multicenter retrospective study in 3 Belgian institutions. We evaluated PFS with T-DM1 in patients treated for HER2 positive metastatic or locally advanced unresectable breast cancer between January 1, 2009 and December 31, 2016. Results We included 51 patients. The median PFS was 9.01 months. The line of treatment in which T-DM1 (1st line, 2nd line, 3rd line or 4+ lines) was administered had no influence on PFS (hazard ratio 0.979, CI95: 0.835–1.143). There was no significant difference in PFS whether or not patients had received prior treatment with capecitabine/lapatinib (9.17 vs 5.56 months, p-value 0.875). But, patients who received pertuzumab before T-DM1 tended to exhibit a shorter PFS (3.55 months for T-DM1 after pertuzumab vs 9.50 months for T-DM1 without pretreatment with pertuzumab), even if this difference was not statistically significant (p-value 0.144). Conclusion Unlike with conventional chemotherapy, the line of treatment in which T-DM1 is administered does not influence PFS in our cohort of patients with advanced HER2-positive breast cancer.A. MigeotteV. DufourA. van MaanenM. BerliereJ. L. CanonD. TaylorF. P. DuhouxBMCarticleMetastatic breast cancerLine of treatmentT-DM1Progression-free survivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Metastatic breast cancer Line of treatment T-DM1 Progression-free survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Metastatic breast cancer Line of treatment T-DM1 Progression-free survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 A. Migeotte V. Dufour A. van Maanen M. Berliere J. L. Canon D. Taylor F. P. Duhoux Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
description	Abstract Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based chemotherapy. We wished to determine if the line of treatment in which T-DM1 is administered has an impact on progression-free survival (PFS) and in particular, if prior treatment with capecitabine/lapatinib or pertuzumab modifies PFS of further treatment with T-DM1. Patients and methods We performed a multicenter retrospective study in 3 Belgian institutions. We evaluated PFS with T-DM1 in patients treated for HER2 positive metastatic or locally advanced unresectable breast cancer between January 1, 2009 and December 31, 2016. Results We included 51 patients. The median PFS was 9.01 months. The line of treatment in which T-DM1 (1st line, 2nd line, 3rd line or 4+ lines) was administered had no influence on PFS (hazard ratio 0.979, CI95: 0.835–1.143). There was no significant difference in PFS whether or not patients had received prior treatment with capecitabine/lapatinib (9.17 vs 5.56 months, p-value 0.875). But, patients who received pertuzumab before T-DM1 tended to exhibit a shorter PFS (3.55 months for T-DM1 after pertuzumab vs 9.50 months for T-DM1 without pretreatment with pertuzumab), even if this difference was not statistically significant (p-value 0.144). Conclusion Unlike with conventional chemotherapy, the line of treatment in which T-DM1 is administered does not influence PFS in our cohort of patients with advanced HER2-positive breast cancer.
format	article
author	A. Migeotte V. Dufour A. van Maanen M. Berliere J. L. Canon D. Taylor F. P. Duhoux
author_facet	A. Migeotte V. Dufour A. van Maanen M. Berliere J. L. Canon D. Taylor F. P. Duhoux
author_sort	A. Migeotte
title	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
title_short	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
title_full	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
title_fullStr	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
title_full_unstemmed	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
title_sort	impact of the line of treatment on progression-free survival in patients treated with t-dm1 for metastatic breast cancer
publisher	BMC
publishDate	2021
url	https://doaj.org/article/935991f59d184ddaad6383fdb13febcd
work_keys_str_mv	AT amigeotte impactofthelineoftreatmentonprogressionfreesurvivalinpatientstreatedwithtdm1formetastaticbreastcancer AT vdufour impactofthelineoftreatmentonprogressionfreesurvivalinpatientstreatedwithtdm1formetastaticbreastcancer AT avanmaanen impactofthelineoftreatmentonprogressionfreesurvivalinpatientstreatedwithtdm1formetastaticbreastcancer AT mberliere impactofthelineoftreatmentonprogressionfreesurvivalinpatientstreatedwithtdm1formetastaticbreastcancer AT jlcanon impactofthelineoftreatmentonprogressionfreesurvivalinpatientstreatedwithtdm1formetastaticbreastcancer AT dtaylor impactofthelineoftreatmentonprogressionfreesurvivalinpatientstreatedwithtdm1formetastaticbreastcancer AT fpduhoux impactofthelineoftreatmentonprogressionfreesurvivalinpatientstreatedwithtdm1formetastaticbreastcancer
_version_	1718429180291448832

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Ejemplares similares